These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1614 related items for PubMed ID: 21762767

  • 1. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S, Bose S, Hur J, Jun K, Kim YK, Cho KS, Koo BS.
    J Ethnopharmacol; 2011 Sep 01; 137(1):783-9. PubMed ID: 21762767
    [Abstract] [Full Text] [Related]

  • 2. Oriental medicine Jangwonhwan reduces Abeta(1-42) level and beta-amyloid deposition in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease.
    Seo JS, Yun JH, Baek IS, Leem YH, Kang HW, Cho HK, Lyu YS, Son HJ, Han PL.
    J Ethnopharmacol; 2010 Mar 02; 128(1):206-12. PubMed ID: 20079417
    [Abstract] [Full Text] [Related]

  • 3. Illite improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer׳s disease through Akt/CREB and GSK-3β phosphorylation in the brain.
    Jeon S, Park JE, Lee J, Liu QF, Jeong HJ, Pak SC, Yi S, Kim MH, Kim CW, Park JK, Kim GW, Koo BS.
    J Ethnopharmacol; 2015 Feb 03; 160():69-77. PubMed ID: 25457987
    [Abstract] [Full Text] [Related]

  • 4. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing.
    Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, Kang J, Kim HJ, Kwon SH, Jang CG, Lee JH, Kim HC, Nah SY.
    J Alzheimers Dis; 2012 Feb 03; 31(1):207-23. PubMed ID: 22543851
    [Abstract] [Full Text] [Related]

  • 5. A modified preparation (LMK03) of the oriental medicine Jangwonhwan reduces Abeta(1-42) level in the brain of Tg-APPswe/PS1dE9 mouse model of Alzheimer disease.
    Seo JS, Jung EY, Kim JH, Lyu YS, Han PL, Kang HW.
    J Ethnopharmacol; 2010 Aug 09; 130(3):578-85. PubMed ID: 20669372
    [Abstract] [Full Text] [Related]

  • 6. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.
    Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR.
    Neurobiol Dis; 2005 Apr 09; 18(3):602-17. PubMed ID: 15755686
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with Aβ3-10 repeat fragment plasmid by reducing Aβ deposition and inflammatory response.
    Ma Y, Li Y, Zong LX, Xing XN, Zhang WG, Cao YP.
    Brain Res; 2011 Jul 11; 1400():112-24. PubMed ID: 21658683
    [Abstract] [Full Text] [Related]

  • 12. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J.
    Neuroscience; 2006 Nov 03; 142(4):941-52. PubMed ID: 16938404
    [Abstract] [Full Text] [Related]

  • 13. Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.
    Choi Y, Jeong HJ, Liu QF, Oh ST, Koo BS, Kim Y, Chung IW, Kim YS, Jeon S.
    Mol Neurobiol; 2017 Jan 03; 54(1):450-460. PubMed ID: 26742522
    [Abstract] [Full Text] [Related]

  • 14. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.
    Guo C, Wang T, Zheng W, Shan ZY, Teng WP, Wang ZY.
    Neurobiol Aging; 2013 Feb 03; 34(2):562-75. PubMed ID: 22717236
    [Abstract] [Full Text] [Related]

  • 15. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice.
    Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, Bradshaw PC.
    J Alzheimers Dis; 2010 Feb 03; 20 Suppl 2():S535-50. PubMed ID: 20463404
    [Abstract] [Full Text] [Related]

  • 16. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N.
    Eur J Pharmacol; 2013 Mar 05; 703(1-3):53-61. PubMed ID: 23276665
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease.
    He J, Luo H, Yan B, Yu Y, Wang H, Wei Z, Zhang Y, Xu H, Tempier A, Li X, Li XM.
    Neurobiol Aging; 2009 Aug 05; 30(8):1205-16. PubMed ID: 18079026
    [Abstract] [Full Text] [Related]

  • 18. Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.
    Seo JS, Lee KW, Kim TK, Baek IS, Im JY, Han PL.
    Free Radic Biol Med; 2011 Jun 01; 50(11):1526-35. PubMed ID: 21382475
    [Abstract] [Full Text] [Related]

  • 19. A butyrolactone derivative 3BDO alleviates memory deficits and reduces amyloid-β deposition in an AβPP/PS1 transgenic mouse model.
    Wei L, Yang H, Xie Z, Yang S, Yang H, Zhao C, Wang P, Xu S, Miao J, Zhao B, Bi J.
    J Alzheimers Dis; 2012 Jun 01; 30(3):531-43. PubMed ID: 22451314
    [Abstract] [Full Text] [Related]

  • 20. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?
    Dragicevic N, Bradshaw PC, Mamcarz M, Lin X, Wang L, Cao C, Arendash GW.
    Neuroscience; 2011 Jun 30; 185():135-49. PubMed ID: 21514369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 81.